|
1
|
Estey EH: Acute myeloid leukemia: 2013
update on risk-stratification and management. Am J Hematol.
88:318–327. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Desai P, Hassane D and Roboz GJ: Clonal
hematopoiesis and risk of acute myeloid leukemia. Best Pract Res
Clin Haematol. 32:177–185. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chang KH, Hwang WL, Muo CH, Hsu CY and
Teng CJ: Outcome and late effects among acute myeloid leukemia
survivors: A nationwide population-based study. Support Care
Cancer. 24:4993–5000. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dohner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P and Larson
RA: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mrozek K, Marcucci G, Nicolet D, Maharry
KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ and
Kohlschmidt J: Prognostic significance of the European LeukemiaNet
standardized system for reporting cytogenetic and molecular
alterations in adults with acute myeloid leukemia. J Clin Oncol.
30:4515–4523. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Deschler B and Lübbert M: Acute myeloid
leukemia: Epidemiology and etiology. Cancer. 107:2099–2107.
2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Junge A, Bacher U, Mueller BU, Keller P,
Solenthaler M and Pabst T: Adverse outcome of AML with aberrant
CD16 and CD56 NK cell marker expression. Hematol Oncol: Jun 3, 2018
(Epub ahead of print).
|
|
8
|
Zahran AM, Mohammed Saleh MF, Sayed MM,
Rayan A, Ali AM and Hetta HF: Up-regulation of regulatory T cells,
CD200 and TIM3 expression in cytogenetically normal acute myeloid
leukemia. Cancer Biomark. 22:587–595. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Cristobal I, Blanco FJ, Garcia-Orti L,
Marcotegui N, Vicente C, Rifon J, Novo FJ, Bandres E, Calasanz MJ,
Bernabeu C and Odero MD: SETBP1 overexpression is a novel
leukemogenic mechanism that predicts adverse outcome in elderly
patients with acute myeloid leukemia. Blood. 115:615–625.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
de Jonge HJ, Valk PJ, Veeger NJ, ter Elst
A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink MM,
Kaspers GJ and Zwaan CM: High VEGFC expression is associated with
unique gene expression profiles and predicts adverse prognosis in
pediatric and adult acute myeloid leukemia. Blood. 116:1747–1754.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Groschel S, Lugthart S, Schlenk RF, Valk
PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF and
Lübbert M: High EVI1 expression predicts outcome in younger adult
patients with acute myeloid leukemia and is associated with
distinct cytogenetic abnormalities. J Clin Oncol. 28:2101–2107.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vasu S, Kohlschmidt J, Mrozek K, Eisfeld
AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D
and Powell BL: Ten-year outcome of patients with acute myeloid
leukemia not treated with allogeneic transplantation in first
complete remission. Blood Adv. 2:1645–1650. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dohner H, Estey EH, Amadori S, Appelbaum
FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D and
Larson RA: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Assi SA, Bonifer C and Cockerill PN:
Rewiring of the transcription factor network in acute myeloid
leukemia. Cancer Inform. 18(1176935119859863)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Thoms JAI, Beck D and Pimanda JE:
Transcriptional networks in acute myeloid leukemia. Genes
Chromosomes Cancer. 58:859–874. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9(559)2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M,
Liu J and Zhao Q: Ten hub genes associated with progression and
prognosis of pancreatic carcinoma identified by co-expression
analysis. Int J Biol Sci. 14:124–136. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu R, Zhang W, Liu ZQ and Zhou HH:
Associating transcriptional modules with colon cancer survival
through weighted gene Co-expression network analysis. BMC Genomics.
18(361)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li S, Liu X, Liu T, Meng X, Yin X, Fang C,
Huang D, Cao Y, Weng H, Zeng X and Wang X: Identification of
biomarkers correlated with the TNM staging and overall survival of
patients with bladder cancer. Front Physiol. 8(947)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kim D, Langmead B and Salzberg SL: HISAT:
A fast spliced aligner with low memory requirements. Nat Methods.
12:357–360. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pertea M, Pertea GM, Antonescu CM, Chang
TC, Mendell JT and Salzberg SL: StringTie enables improved
reconstruction of a transcriptome from RNA-seq reads. Nat
Biotechnol. 33:290–295. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578.
2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Touw IP and van de Geijn GJ: Granulocyte
colony-stimulating factor and its receptor in normal myeloid cell
development, leukemia and related blood cell disorders. Front
Biosci. 12:800–815. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Elliott MA and Tefferi A: Chronic
neutrophilic leukemia: 2018 update on diagnosis, molecular genetics
and management. Am J Hematol. 93:578–587. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Maxson JE, Ries RE, Wang YC, Gerbing RB,
Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y and Zong Z:
CSF3R mutations have a high degree of overlap with CEBPA mutations
in pediatric AML. Blood. 127:3094–3098. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Su L, Gao S, Tan Y, Lin H, Liu X, Liu S,
Yang Y, Sun J and Li W: CSF3R mutations were associated with an
unfavorable prognosis in patients with acute myeloid leukemia with
CEBPA double mutations. Ann Hematol. 98:1641–1646. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tenorio J, Alvarez I, Riancho-Zarrabeitia
L, Martos-Moreno GA, Mandrile G, de la Flor Crespo M, Sukchev M,
Sherif M, Kramer I and Darnaude-Ortiz MT: Molecular and clinical
analysis of ALPL in a cohort of patients with suspicion of
Hypophosphatasia. Am J Med Genet A. 173:601–610. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bencze J, Morotz GM, Seo W, Bencs V,
Kalman J, Miller CCJ and Hortobágyi T: Biological function of Lemur
tyrosine kinase 2 (LMTK2): Implications in neurodegeneration. Mol
Brain. 11(20)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Conti A, Majorini MT, Fontanella E,
Bardelli A, Giacca M, Delia D, Mano M and Lecis D: Lemur tyrosine
kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis
by regulating the levels of the BCL2 family members. Cancer Lett.
389:59–69. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Parameswaran R, Ramakrishnan P, Moreton
SA, Xia Z, Hou Y, Lee DA, Gupta K, deLima M, Beck RC and Wald DN:
Repression of GSK3 restores NK cell cytotoxicity in AML patients.
Nat Commu. 7(11154)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
van Galen P, Hovestadt V, Wadsworth Ii MH,
Hughes TK, Griffin GK, Battaglia S, Verga JA, Stephansky J, Pastika
TJ and Lombardi Story J: Single-cell RNA-seq reveals AML
hierarchies relevant to disease progression and immunity. Cell.
176:1265–81.e24. 2019.PubMed/NCBI View Article : Google Scholar
|
